Price: $217.79, Change: $+7.21, Percent Change: +3.42%
Related Articles
Wire
Update: Snap Acquires Augmented Reality Firm Illumix
(Updates with the company's comments throughout and latest stock move in the fifth paragraph.)Snap (SNAP) has acquired spatial augmented reality firm Illumix, a company spokesperson confirmed through email toThursday.Financial details related to the acquisition were not provided.Illumix's technology, platform, and the majority of its team members will join Snap to support AR efforts, including AR for Specs, the spokesperson said.Snap will continue to work with Illumix's existing customers and partners, including major theme parks, the spokesperson added.Shares of the company were up 4.5% in Thursday trading.Price: $5.99, Change: $+0.26, Percent Change: +4.45%
$SNAP
Wire
Update: Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case
(Updates with Amarin's response to a request for comment in the penultimate paragraph.)The US Supreme Court on Thursday ruled that Amarin (AMRN) failed to prove that a generic-drug manufacturer actively induced other companies to infringe upon two of its Vascepa patents after the generic maker received approval for a so-called "skinny-label" version of the drug.Vascepa received Food and Drug Administration approval in 2012 for treating severe hypertriglyceridemia before receiving the FDA's go-ahead in 2019 for a second, more common use: lowering cardiovascular risk in hypertriglyceridemia patients who take statins, the so-called CV indication, for which it received two patents, the Supreme Court noted.Hikma Pharmaceuticals received FDA approval for a generic icosapent ethyl skinny label in 2020 that carves out Vascepa's still-patented CV-indication method of use, the court noted."Amarin has failed to state a claim for active inducement in violation of *271(b), so its complaint cannot withstand Hikma's motion to dismiss," the Supreme Court said."We are deeply disappointed by the Supreme Court's decision today and are evaluating our next steps," Amarin toldin a statement. "Amarin remains fiercely dedicated to its primary mission: ensuring VASCEPA/VAZKEPA, a groundbreaking, innovative, and cost-effective therapy, reaches patients across the world who would benefit from this life-changing treatment."Hikma didn't immediately reply to a request for comment from.Price: $14.17, Change: $-0.36, Percent Change: -2.48%
$AMRN
Wire
Boeing 787-9 Dreamliner Nose Gear Retracts at Frankfurt Airport Gate, Lufthansa Says
A Boeing (BA) 787 Dreamliner's nose gear unexpectedly retracted while parked at a gate at Frankfurt airport, aircraft operator Lufthansa said.Several crew members and ground staff who were on board the aircraft sustained injuries and are undergoing medical treatment, Lufthansa said Thursday in an emailed statement to.The incident occurred before passengers had boarded the aircraft, which was scheduled to depart for Los Angeles as flight LH450, Lufthansa said."We are currently investigating the exact circumstances together with the relevant authorities," Lufthansa said.Boeing and Frankfurt Airport did not immediately respond to requests for comment from.Price: $217.13, Change: $+6.55, Percent Change: +3.11%
$BA